Arthneeti

Metropolis Healthcare Q1 FY27 Share Price & Earnings Call Analysis

₹545.65-1.48% today
Market cap
₹11,320 Cr
P/E
54.38
ROE
13.63%
PEG
5.09
Price to sales
6.62
Debt to equity
0.15
52W high / low
₹2,050 / ₹422
Sales growth (5Y)
10.52%
EBITDA margin
24.69%
Net profit margin
11.85%
Promoter holding
47.82%
Sales (last year)
₹1,710 Cr

Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.

Guidance scorecard · Q1 FY27 call

What Metropolis Healt's management guided
and where it ranks in Healthcare Services

#21of 33 in
Healthcare Services
Revenue10–20%MarginsUp 2%+CapexPlannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ1 FY27 call

10–20%
  • North India currently contributes 18% to revenue and is expected to grow faster, potentially increasing contribution to 25% in the next few years.
  • East India currently 6%, with limited investment so far; future investments may increase contribution.
  • Overall revenue growth is volume-driven, with expansion focused on Tier 2 and Tier 3 towns through increased centers without adding more labs, improving penetration and customer reach.
  • Specialty and genomics segments are key growth drivers, expecting disproportionate growth due to hospital expansions in Tier 2/3 towns.
  • Addition of 1,000 more centers in 3 years planned, including 100 mini hubs offering radiology and allied services, enhancing service portfolio and customer engagement.
  • TruHealth wellness portfolio to grow from 18% to 25% contribution.
  • Home collection services (~11-12% revenue) have substantial growth potential.

2 more points from Metropolis Healt's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Up 2%+

See what Metropolis Healt said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • Metropolis is evaluating two models for radiology center expansion: capex and opex.
  • If investing via capex, the approximate cost per center is INR 35-40 lakhs for equipment like X-ray, ultrasound, treadmill, DEXA scan.
  • Plan to experiment with 50 centers in the first year, followed by another 50 next year, focusing on location and service quality.
  • The business prioritizes disciplined capital allocation with a capital-light approach overall.
  • Ongoing reinvestments in technology, digital automation, AI, and expansion of labs and centers ensure long-term relevance and growth.
  • They are investing in allied healthcare services and specialty portfolios, possibly via asset-light models and subscription programs.

2 more points from Metropolis Healt's call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

See what Metropolis Healt said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

Ask what Metropolis Healt said on the order book →

Full Q1 FY27 analysis
Full Healthcare Services ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Healthcare Services
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Aster DM Quality Care LtdGood growth
    3
See all potential multibaggersWhere does Metropolis Healt rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Healthcare Services companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹903 Cr—
240%+Flat₹583 Cr22.2
3Aster DM Quality Care Ltd20–40%Up 2%+₹58,782 Cr162.9
420–40%Up 0–2%₹1,730 Cr17.5
520–40%Up 0–2%₹580 Cr11.9
620–40%Flat₹1.13L Cr53.9

Sign up free to see every company in the sector ranking and track Metropolis Healt.

Pro shows every company guiding 40%+ revenue growth →Full Healthcare Services ranking

Financials of Metropolis Healt

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Metropolis Healt

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +49.74%49.67%49.62%49.43%49.40%48.89%48.89%48.89%48.87%48.86%48.86%47.82%
FIIs +21.66%18.90%18.25%18.56%16.73%15.29%12.83%12.52%11.68%10.43%11.03%11.67%
DIIs +20.73%24.86%27.42%28.02%30.00%30.30%32.40%33.10%34.73%35.80%35.12%35.49%
Public +7.87%6.57%4.69%3.98%3.86%5.51%5.87%5.48%4.69%4.92%5.00%5.02%
No. of Shareholders79,87868,28358,10851,85248,57249,29350,01547,84646,67049,17550,63650,592

Pros & Cons

Metropolis Healt

Key positives and risks surfaced from the company insights section.

Pros
  • Stock is trading at 7.48 times its book value
  • Promoter holding has decreased over last quarter: -1.04%
  • The company has delivered a poor sales growth of 10.5% over past five years.
  • Company has a low return on equity of 12.4% over last 3 years.
Raw Insights
  • Stock is trading at 7.48 times its book value
  • Promoter holding has decreased over last quarter: -1.04%
  • The company has delivered a poor sales growth of 10.5% over past five years.
  • Company has a low return on equity of 12.4% over last 3 years.

Financials of Metropolis Healt

Quarterly Results

Quarter-by-quarter operating performance

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales +277308291331313350323345386429406425450
Expenses +214234226251235260251283296321311317339
Operating Profit63756580799072629010895108111
OPM %23%24%22%24%25%26%22%18%23%25%23%25%25%
Other Income +3123233781-085
Interest6656555556686
Depreciation21222526262728293132323932
Profit before tax39483751516142366171577078
Tax %26%26%26%28%25%24%26%19%26%26%26%27%27%
Net Profit +29362737384731294553425157
EPS in Rs1.411.731.331.781.852.271.531.412.172.542.002.462.73

Financials of Metropolis Healt

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +4564755456477618569981,2281,1481,2081,3311,6461,710
Expenses +3393594054675596197088808559201,0231,2401,288
Operating Profit117116140181203237290348293288308406422
OPM %26%24%26%28%27%28%29%28%26%24%23%25%25%
Other Income +7293968-171234159151614
Interest222441312253228242926
Depreciation21171719203946638994109134135
Profit before tax101128160164187169244293188175191259276
Tax %33%36%33%32%34%24%25%27%24%26%24%26%
Net Profit +6882107112124128183215143128146191203
EPS in Rs2.973.875.125.255.996.298.9510.466.986.247.009.179.73
Dividend Payout %0%100%49%0%55%32%22%19%29%16%0%55%

Financials of Metropolis Healt

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital101010101010101010101041
Reserves3522693144054085136968769781,0861,3211,472
Borrowings +145111867112379266197204232
Other Liabilities +87107188110113160181256240254324386
Total Liabilities4623915125265507501,0001,5211,4951,5471,8592,131
Fixed Assets +1531422022072132963431,0591,1211,1771,4471,601
CWIP0110630620000
Investments16810114210233141016155571142
Other Assets +141147167216298437647440340316341387
Total Assets4623915125265507501,0001,5211,4951,5471,8592,131

Financials of Metropolis Healt

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +699110210490215249253247264263351
Cash from Investing Activity +-5696-86136-10463-73648-89-199-220
Cash from Financing Activity +-9-174-17-87-118-55-33163-292-181-87-115
Net Cash Flow414-118856279-3213-6-2315
Free Cash Flow4679459067179221223195200196300
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit87%113%109%89%78%118%106%96%102%105%99%98%

Financials of Metropolis Healt

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days575454576655454039384138
Inventory Days524638535544596864586551
Days Payable9296978890152160136136150171146
Cash Conversion Cycle173-52130-54-56-29-33-53-65-57
Working Capital Days328-2728332-9-26-22-16-18-15
ROCE %28%34%46%43%43%40%36%29%17%16%15%18%

Guidance history

How Metropolis Healt's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%Up 2%+Planned——
Q1 FY27 call →10–20%Up 2%+Planned——
Q4 FY26 call →10–20%FlatPlanned——
Q3 FY26 call →10–20%FlatPlanned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

34out of 100

Momentum score · price trend

34 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+8.8%69%
Last 6 months+12.4%71%
Last 3 months−2.7%62%

The price is 38.3% below its all-time high of ₹860.23 (31 Dec 2021). Stocks more than 20% below their peak have their score halved, so 68 became 34.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Metropolis Healt: 0.4 × 69 + 0.4 × 71 + 0.2 × 62 = 68, halved to 34 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 16 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Metropolis Healt's management said in earlier quarters

Others in Healthcare Services this season

  • Rainbow Childrens Medicare Ltd (Q2 FY27)

    Year-on-year (YoY) growth in revenue: 23.2% . Key investor presentation takeaways from Rainbow Childrens Medicare Ltd's Q2 FY27 investor presentation — and how

  • Narayana Hrudayalaya Ltd (Q2 FY27)

    Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27

  • Artemis Medicare Services Ltd (Q2 FY27)

    Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service

  • Max Healthcare Institute Ltd (Q2 FY27)

    Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio

Compare:vs Apollo Hospitals Enterprise Ltdvs Manipal Health Enterprises Ltdvs Max Healthcare Institute Ltd